Interleukin‐12: Murine Models of a Potent Antitumor Agent a

[1]  J. Franco,et al.  Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. , 1996, Journal of the National Cancer Institute.

[2]  H. Fujiwara,et al.  Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. , 1995, Cancer research.

[3]  L. Zitvogel,et al.  Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. , 1995, Research in immunology.

[4]  H. Fujiwara,et al.  A sequence of cellular and molecular events involved in IL12-induced tumour regression. , 1995, Research in immunology.

[5]  L. Zitvogel,et al.  Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. , 1995, Journal of immunology.

[6]  H. Fujiwara,et al.  Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. , 1995, International immunology.

[7]  L. Zitvogel,et al.  Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. , 1995, Journal of immunology.

[8]  Hendrzak Ja,et al.  Interleukin-12. Biologic activity, therapeutic utility, and role in disease. , 1995 .

[9]  A. Khar,et al.  AK-5 tumor-induced expression of interleukin-12: role of IL-12 in NK-mediated AK-5 regression. , 1995, Cellular immunology.

[10]  R. D'Amato,et al.  Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.

[11]  Yao-Tseng Chen,et al.  Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Trinchieri,et al.  IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. , 1995, Journal of immunology.

[13]  L. Luistro,et al.  Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[14]  G. Trinchieri,et al.  CD4 T cells inhibit in vivo the CD8‐mediated immune response against murine colon carcinoma cells transduced with interleukin‐12 genes , 1995, European journal of immunology.

[15]  G. Trinchieri,et al.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.

[16]  A. Cesano,et al.  Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. , 1994, The Journal of clinical investigation.

[17]  R. Schreiber,et al.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.

[18]  G. Trinchieri,et al.  B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation , 1994, The Journal of experimental medicine.

[19]  G. Trinchieri,et al.  Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells , 1994, The Journal of experimental medicine.

[20]  M. Gately,et al.  Antitumor activity of interleukin-12. , 1994, Clinical immunology and immunopathology.

[21]  B. Perussia,et al.  Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. , 1994, Cancer research.

[22]  J. Ritz,et al.  Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies , 1993 .

[23]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[24]  A. Składanowski,et al.  Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. , 1993, Biochemical pharmacology.

[25]  R. Dziadziuszko,et al.  Interleukin 12 augments natural killer-cell mediated cytotoxicity in hairy cell leukemia. , 1993, Leukemia & lymphoma.

[26]  A. Bradley,et al.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. , 1993, Science.

[27]  M. Gately,et al.  Regulation of human cytolytic lymphocyte responses by interleukin-12. , 1992, Cellular immunology.

[28]  P. Familletti,et al.  Cloning and expression of murine IL-12. , 1992, Journal of immunology.

[29]  M. Gately,et al.  IL-12 receptor. II. Distribution and regulation of receptor expression. , 1992, Journal of immunology.

[30]  B. Naume,et al.  A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. , 1992, Journal of immunology.

[31]  P. Familletti,et al.  Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Hewick,et al.  Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. , 1991, Journal of immunology.

[33]  A. Cesano,et al.  Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line. , 1995, Cancer research.

[34]  M. Gately,et al.  Interleukin-12: a pivotal regulator of cell-mediated immunity. , 1995, Cancer treatment and research.

[35]  D. Carvajal,et al.  Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. , 1994, International immunology.

[36]  B. Ksander,et al.  IL-12 ABROGATES IMMUNE PRIVILEGE IN THE ANTERIOR CHAMBER OF THE EYE , 1994 .

[37]  Simon C Watkins,et al.  Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. , 1994, Cancer research.